Mind Medicine Inc (NASDAQ: MNMD) shares are trading lower in Tuesday's after-hours session after the company announced a proposed public offering of common shares.
The clinical trial investigating the effects of MDMA analogs in healthy volunteers led by PI Prof. Dr. Matthias Liechti and supported by psychedelics biotech company Mind Medicine Inc. (NASDAQ: MNMD) has begun patient dosing.
The psychedelics landscape changes quickly. Whether large or small, every biotech company is looking for ways to further advance their research and product & services commercialization.